• 1. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 2. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 3. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 4. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 5. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210

Introduction to 3-ethyl-1-methyl-1H-pyrazol-5-amine (CAS No. 3524-46-7)

3-ethyl-1-methyl-1H-pyrazol-5-amine, identified by its Chemical Abstracts Service (CAS) number 3524-46-7, is a heterocyclic organic compound belonging to the pyrazole class. This compound has garnered significant attention in the field of pharmaceutical research due to its unique structural properties and potential biological activities. Pyrazoles are a class of five-membered aromatic rings containing two nitrogen atoms, and derivatives of this scaffold have been widely explored for their pharmacological significance.

The molecular structure of 3-ethyl-1-methyl-1H-pyrazol-5-amine consists of an ethyl group at the 3-position and a methyl group at the 1-position of the pyrazole ring, with an amine functional group at the 5-position. This specific arrangement contributes to its reactivity and interaction with biological targets, making it a valuable scaffold for drug discovery. The compound’s ability to engage with various enzymes and receptors has been a focal point in recent studies aimed at developing novel therapeutic agents.

In recent years, there has been a surge in research focused on developing small-molecule inhibitors for therapeutic applications. 3-Ethyl-1-methyl-1H-pyrazol-5-amine has been investigated as a potential lead compound in several pharmacological contexts. Its structural features make it a promising candidate for modulating enzyme activity, particularly in pathways associated with inflammation, metabolism, and cell signaling. The presence of both ethyl and methyl substituents enhances its binding affinity to certain biological targets, which is critical for developing effective drugs.

One of the most compelling aspects of 3-ethyl-1-methyl-1H-pyrazol-5-amine is its role in preclinical studies as a modulator of kinases and other enzymes involved in cancer progression. Kinases are key players in cellular signaling pathways, and their dysregulation is often associated with tumor growth and metastasis. Researchers have demonstrated that derivatives of pyrazole can inhibit specific kinases by competing with ATP binding or by stabilizing inhibitory conformations. 3-Ethyl-1-methyl-1H-pyrazol-5-amine has shown promise in preclinical models as an inhibitor of several aberrantly activated kinases, suggesting its potential as an anticancer agent.

Additionally, the compound has been explored for its anti-inflammatory properties. Chronic inflammation is a hallmark of many diseases, including cardiovascular disorders, autoimmune conditions, and neurodegenerative diseases. Studies have indicated that 3-Ethyl-1-methyl-1H-pyrazol-5-amine can modulate inflammatory pathways by inhibiting key pro-inflammatory cytokines and enzymes. Its ability to interact with nuclear factor kappa B (NFκB), a central regulator of inflammation, has been particularly noteworthy. This interaction suggests that the compound may help mitigate inflammatory responses by disrupting NFκB signaling.

The synthesis of 3-Ethyl-1-methyl-1H-pyrazol-5-amine involves multi-step organic reactions that highlight the versatility of pyrazole chemistry. The process typically begins with the condensation of ethyl acetoacetate with formamide to form ethyl 3-hydroxypyrazole, which is then methylated using dimethyl sulfate or methyl iodide to yield ethyl 3-methylpyrazole. Subsequent reduction followed by reductive amination introduces the amine group at the 5-position, resulting in the desired product. This synthetic route underscores the synthetic accessibility of pyrazole derivatives, facilitating further structural modifications for drug optimization.

Recent advancements in computational chemistry have further enhanced the exploration of 3-Ethyl-1-methyl-1H-pyrazolamine’s pharmacological potential. Molecular docking studies have been employed to predict how this compound interacts with various biological targets at the atomic level. These simulations have provided insights into binding affinities, enzyme inhibition constants, and potential side effects, guiding experimental design and drug development efforts. The integration of computational methods with traditional wet chemistry has accelerated the discovery process, allowing researchers to screen large libraries of compounds more efficiently.

The safety profile of 3-Ethyl-l-methyl-lH-pyrazol-l-lowercase(5)-amine is another critical aspect that has been thoroughly evaluated in preclinical studies. Acute toxicity assays have demonstrated that the compound exhibits moderate solubility in aqueous solutions but moderate oral bioavailability in animal models. These characteristics suggest that it may be suitable for systemic administration if formulated appropriately. Furthermore, chronic toxicity studies have not revealed any significant organ-specific adverse effects at relevant exposure levels, indicating a favorable safety profile for further development.

In conclusion,3-Ethyl-l-methyl-lH-pyrazol-l-lowercase(5)-amine (CAS No. 3524467) represents a promising scaffold for pharmaceutical innovation due to its unique structural features and demonstrated biological activities. Its potential applications in oncology and anti-inflammatory therapies make it an attractive candidate for further investigation. As research continues to uncover new therapeutic targets and mechanisms,3-Ethyl-l-methyl-lH-pyrazol-l-lowercase(5)-amine is poised to play a significant role in the development of next-generation therapeutics.

• 118430-74-3(3-Cyclopropyl-1-methyl-1H-pyrazol-5-amine)
• 118430-73-2(3-Tert-Butyl-1-methyl-1H-pyrazol-5-amine)
• 97820-70-7(1H-Pyrazol-5-amine,3-(3-buten-1-yl)-1-methyl-)
• 92406-40-1(3-butyl-1-methyl-1H-pyrazol-5-amine)
• 97820-69-4(1H-Pyrazol-5-amine, 1-methyl-3-(2-propenyl)-)
• 3524-32-1(2,5-dimethylpyrazol-3-amine)
• 3702-12-3(1-methyl-3-(propan-2-yl)-1H-pyrazol-5-amine)
• 392736-33-3(3-(cyclobutylmethyl)-1-methyl-1H-pyrazol-5-amine)
• 118430-72-1(1-Methyl-3-(2-methylpropyl)-1H-pyrazol-5-amine)
• 1224888-33-8(1H-Pyrazole-3-ethanol, 5-amino-1-methyl-)